TY  - JOUR
T1  - Investigating the Changing Levels of Immune Checkpoint Proteins in the Serum of Breast Cancer Patients
A1  - Jehan Alrahimi
A1  - Mahi Yousuf
A1  - Peter Pushparaj
A1  - Fatemah Basingab
A1  - Kawther Zaher
A1  - Mohammed Hassan
A1  - Eman Alghamdi
A1  - Kaltoom Al-Sakkaf
A1  - Alia Aldahlawi
JF  - Pharmacophore
JO  - Pharmacophore
SN  - 2229-5402
Y1  - 2022
VL  - 13
IS  - 6
DO  - 10.51847/FUdiHNoW6W
SP  - 125
EP  - 136
N2  - Breast cancer is the most frequent kind of invasive cancer in women. Biomarker monitoring and prognosis provide outstanding clinical information that may be employed to battle various cancers. This study aimed to examine a variety of biomarkers utilizing a multiplex bead array. BTLA, CD27, CD28, TIM-3, HVEM, CD40, LAG-3, TLR-2, PD-1, CD80, CD86, PDL-1, PDL-2, and ICOS are common biomarker checkpoint proteins found in a selective panel. This panel examined a research group of 59 patients with BC and 17 healthy people. The expression patterns of a handful of the fourteen biomarkers varied considerably between people with BC and healthy controls. With P-values of (p= 0.05), (p= 0.02), (p= 0.01), and (p= 0.02), general features of the two groups of malignant and non-malignant patients revealed significant correlations in parameters such as the age of first menstruation, pregnancy, menopausal status, and hormone replacement treatment. With P- values, there was a substantial rise in BTLA, HVEM, TLR-2, and PDL-1 serum levels, as well as a significant drop in CD86. Furthermore, these markers indicated a significant relationship with the clinic-pathological aspects of the patients. With a P-value of 0.0002, both BTLA and HVME showed a statistically significant connection with hormone receptor phenotypes. For ER status, BTLA, CD86, and PDL1 had equivalent significance values of (p= 0.0148), (p= 0.0166), and (p= 0.0001). BTLA was related to lymph node involvement (p=0.0397), whereas TLR2 was associated with HER2 status (p=0.0332). BTLA, HVEM, TLR-2 CD86, and PDL-1 may be valuable biomarkers for cancer monitoring and prognosis.
UR  - https://pharmacophorejournal.com/article/investigating-the-changing-levels-of-immune-checkpoint-proteins-in-the-serum-of-breast-cancer-patien-m3dkoo3ql12nsd5
ER  -